ARTICLE | Politics, Policy & Law
GAO finds little evidence Priority Review program spurring drug development
February 8, 2020 1:26 AM UTC
There is little evidence that the U.S. rare pediatric disease Priority Review voucher program has incentivized development of medicines, according to a Government Accountability Office report.
The report could influence Congress, which is facing a Sept. 30 deadline to reauthorize the voucher program. If not renewed, the program would end in September 2022. ...